Artiva CEO granted 155K options, 45K RSUs

Artiva Biotherapeutics’ CEO received new option and RSU awards that increase his direct equity holdings.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that its Chief Executive Officer, Fred Aslan, received equity awards on September 10, 2026. He was granted 155,000 stock options with an exercise price of $10.42 per share, expiring on September 9, 2036, and a separate award of 45,000 restricted stock units under the 2024 Equity Incentive Plan. Following the restricted stock unit grant, Aslan directly holds 1,494,765 shares of common stock. The stock options begin vesting on September 8, 2026 in equal monthly installments over four years. No Rule 10b5-1 trading plan is reported for these awards.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 2 txns

Insider Aslan Fred

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy) F2	155,000	$0.00	$0.00
Grant/Award	Common Stock F1	45,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 155,000 contracts (Direct); Common Stock — 1,494,765 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
2. F2. Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.

Key Figures

Stock options granted: 155,000 options Option exercise price: $10.42 per share Option expiration date: September 9, 2036 +3 more

6 metrics

Stock options granted 155,000 options Options on Artiva Biotherapeutics common stock granted to the CEO on September 10, 2026

Option exercise price $10.42 per share Exercise price for the 155,000 stock options granted on September 10, 2026

Option expiration date September 9, 2036 Expiration of the CEO’s 155,000 stock options

Restricted stock units granted 45,000 units Restricted stock unit award granted to the CEO on September 10, 2026

CEO common shares after grant 1,494,765 shares Direct holdings of Artiva Biotherapeutics common stock following the restricted stock unit grant

Option vesting rate 1/48th monthly Portion of option shares vesting each month beginning September 8, 2026, over four years

Key Terms

restricted stock unit, 2024 Equity Incentive Plan, vest

3 terms

restricted stock unit financial

"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

2024 Equity Incentive Plan financial

"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."

vest financial

"Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did the CEO receive in this Form 4 for ARTV?

Fred Aslan, CEO of ARTV, received 155,000 stock options at an exercise price of $10.42 per share and a separate grant of 45,000 restricted stock units on September 10, 2026.

How many ARTV common shares does the CEO hold after these transactions?

After the September 10, 2026 restricted stock unit grant, Fred Aslan directly holds 1,494,765 shares of Artiva Biotherapeutics common stock.

What are the key terms of the new stock options reported for ARTV’s CEO?

The option grant covers 155,000 shares of Artiva Biotherapeutics common stock at an exercise price of $10.42 per share and expires on September 9, 2036.

How do the ARTV CEO’s new options vest over time?

Beginning on September 8, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four-year period, resulting in full vesting after four years.

Were the ARTV CEO’s equity awards granted under a company plan?

Yes. The 45,000 restricted stock units were granted under Artiva Biotherapeutics’ 2024 Equity Incentive Plan, as disclosed in the Form 4 footnotes.

Were the ARTV CEO’s reported equity awards made under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan is associated with these reported equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 08:07 PM Accepted by SEC EDGAR 09/14/2026 - 08:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aslan Fred

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		A		45,000(1)	A	$0	1,494,765	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$10.42	09/10/2026		A		155,000		(2)	09/09/2036	Common Stock	155,000	$0	155,000	D

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

2. Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.

	/s/ Jennifer Bush, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)